Individuals undergoing RYGB or sleeve gastrectomy lost up to 20 percent of their initial BMI; many had remission from T2DM, HTN, hyperlipidemia
WEDNESDAY, June 16, 2021 (HealthDay News) — For individuals with class 1 obesity, bariatric surgery is effective for weight loss and comorbidity resolution, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held virtually from June 10 to 12.
Maria S. Altieri, M.D., from East Carolina University in Greenville, North Carolina, and colleagues accessed deidentified electronic health records to identify adult patients with class 1 obesity undergoing Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG; 566 and 730 patients, respectively). Resolution of comorbidities and weight loss outcomes were compared at three years after surgery.
The researchers found that patients lost up to 20 percent of their initial body mass index (BMI). Associations with greater weight loss were seen for those who were younger, females, and those with an obesity-related comorbidity. The likelihood of being in remission from type 2 diabetes reached 45 percent at about two years after surgery. For hypertension, remission probabilities were 60 and 50 percent for RYGB and SG, respectively, at three years after surgery. The probabilities of remission from hyperlipidemia were close to 50 and 25 percent for RYGB and SG, respectively, at two years. No between-group differences were seen between BMI trajectories and remission from type 2 diabetes.
“This study confirms the effectiveness of bariatric surgery in patients with Class 1 obesity in real-world settings and suggests earlier intervention in patients with less severe disease should be considered,” Altieri said in a statement.
Copyright © 2021 HealthDay. All rights reserved.
